Skip to content

NEJM evidence

ISSN 2766-5526

1 paper in the library · publishing 2023

Papers

Sort Most recent Most cited

Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.

NEJM evidence September 2023 Philip E Mosley, Lachlan Webb, Anastasia Suraev et al.

BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There is preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety. METHODS: In this double-blind, crossover trial, participants with severe Tourette syndrome were randomly assigned to a...